A Systematic Review of Long-Term Safety Outcomes of Ketamine and Esketamine in Patients with Treatment-Resistant Depression
{{output}}
Introduction: Approximately 30-40% of patients with major depressive disorder fail to respond to conventional antidepressants. Ketamine and esketamine are increasingly used in maintenance protocols extending months to years, yet ... ...
